Plain English Summary
Background and study aims
Gastric cancer (GC) is the second leading cause of cancer-related mortality worldwide. Therefore, identifying the predictive factors for surgical morbidity, disease recurrence, and long-term survival is necessary for preventing GC patient mortality. We aimed to evaluate the factors that contribute to the poor prognoses of GC patients.
Who can participate?
All post-curative resection gastric cancer patients.
What does the study involve?
All patients underwent total or distal gastrectomy, and we gave chemotherapy to the patient whom a state has good.
What are the possible benefits and risks of participating?
No benefits and risks of participating.
Where is the study run from?
Onomichi General Hospital
When is the study starting and how long is it expected to run for?
May 2011 to June 2017.
Who is funding the study?
Investigator-initiated and funded.
Who is the main contact?
Hitomi Takechi, firstname.lastname@example.org
Dr Hitomi Takechi
+81 848 22 8111
Using the preoperative prognostic nutritional index as a predictive factor for non-cancer-related death in post-curative resection gastric cancer patients: a retrospective study
We aimed to evaluate the factors that contribute to the poor prognoses of gastric cancer patients.
Approved 14/03/2019, Ethical Review Board of Onomichi General Hospital (1-10-23, Hirahara, Onomichi-shi, Hiroshima, 722-8508, Japan; +81-848-22-8111), ref: OJH-201892.
Retrospective, single-centre, observational, longitudinal study
Primary study design
Secondary study design
Patient information sheet
Not available in web format, please use contact details to request a participant information sheet.
All patients underwent total or distal gastrectomy and D1+ or D2 lymph node dissection in accordance with the Japanese Gastric Cancer Treatment Guidelines published in 2010 (ver. 3). All patients were histologically confirmed to have stage I, II, or III gastric adenocarcinomas and underwent total or distal gastrectomy. The total duration of observation and follow-up were conducted within 5 years post-operation, or until death.
Primary outcome measure
1. Disease-free survival is defined as the time between the date of surgery and disease recurrence or the last available follow-up.
2. Overall survival is defined as the time between the date of surgery and death or the last available follow-up.
Secondary outcome measures
1. Absolute neutrophil and lymphocyte counts are measured using routine blood and biochemical tests on the day before surgery.
2. Serum albumin is measured using routine blood and biochemical tests on the day before surgery.
3. C-reactive protein (CRP) concentrations are measured using routine blood and biochemical tests on the day before surgery.
4. Prognosis is measured using the modified Glasgow Prognosis Score, perineural invasion and neutrophil to lymphocyte ratio on the day before surgery.
5. Diagnosis is determined using surgical pathology reports after surgery.
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
Post-curative resection gastric cancer patients
Target number of participants
Participant exclusion criteria
Recruitment start date
Recruitment end date
Countries of recruitment
Trial participating centre
Department of Surgery, Onomichi General Hospital
1-10-23, Hirahara, Onomichi-shi
Investigator initiated and funded
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Planned publication in BMC Gastroenterology.
IPD sharing statement: the datasets generated during and/or analysed during the current study are/will be available upon request from Hitomi Takechi (email@example.com). The data will be available for 5 years.
Intention to publish date
Participant level data
Available on request
Basic results (scientific)